Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease.

Literature DB >> 21186169

Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease.

Navtej Sathi, Thomas Urwin, Sean Desmond, Julie K Dawson.

Abstract

Entities: Disease Species

Mesh：

Substances：
Antirheumatic Agents

Year: 2010 PMID： 21186169 DOI： 10.1093/rheumatology/keq426

Source DB: PubMed Journal: Rheumatology (Oxford) ISSN： 1462-0324 Impact factor: 7.580

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Authors: Qiang Fu; Li Wang; Luling Li; Yifan Li; Ran Liu; Yi Zheng
Journal: Clin Rheumatol Date: 2018-12-07 Impact factor: 2.980

Review 2. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors: Kundan Iqbal; Clive Kelly
Journal: Ther Adv Musculoskelet Dis Date: 2015-12 Impact factor: 5.346

3. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.

Authors: Jorge Rojas-Serrano; Denisse Herrera-Bringas; Diana I Pérez-Román; Renzo Pérez-Dorame; Heidegger Mateos-Toledo; Mayra Mejía
Journal: Clin Rheumatol Date: 2017-06-06 Impact factor: 2.980

Review 4. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

Authors: Tracy J Doyle; Joyce S Lee; Paul F Dellaripa; James A Lederer; Eric L Matteson; Aryeh Fischer; Dana P Ascherman; Marilyn K Glassberg; Jay H Ryu; Sonye K Danoff; Kevin K Brown; Harold R Collard; Ivan O Rosas
Journal: Chest Date: 2014-03-01 Impact factor: 9.410

5. Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis.

Authors: Alberto Daniel Rocha-Muñoz; Manuel Ponce-Guarneros; Jorge Ivan Gamez-Nava; Eva Maria Olivas-Flores; Mayra Mejía; Pablo Juárez-Contreras; Erika Aurora Martínez-García; Esther Guadalupe Corona-Sánchez; Tania Marlen Rodríguez-Hernández; Mónica Vázquez-del Mercado; Mario Salazar-Páramo; Arnulfo Hernan Nava-Zavala; Ernesto German Cardona-Muñoz; Alfredo Celis; Laura González-Lopez
Journal: J Immunol Res Date: 2015-05-19 Impact factor: 4.818

Review 10. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors: Shunsuke Mori
Journal: Clin Med Insights Circ Respir Pulm Med Date: 2015-09-08

Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease.

1. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Review 2. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

3. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.

Review 4. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

5. Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis.

Review 6. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

7. The challenges in classifying rheumatoid arthritis-associated interstitial lung disease.

8. Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis.

Review 9. The safety of biologic therapies in RA-associated interstitial lung disease.

Review 10. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.